Skip to main content

Table 4 Subgroup analysis for all-cause mortality at 30 days

From: Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry

 

Event/total (%)

Unadjusted models

Adjusted models

1–2 SMuRFs vs no SMuRFs

3–4 SMuRFs vs no SMuRFs

Pinteraction

1–2 SMuRFs vs no SMuRFs

3–4 SMuRFs vs no SMuRFs

Pinteraction

Age

   

0.27

  

0.20

 <55

129/4834 (2.7)

0.85 (0.49–1.49)

0.67 (0.34–1.32)

 

1.76 (0.81–3.81)

1.79 (0.73–4.39)

 

 55–<75

597/8659 (6.9)

0.95 (0.74–1.22)

0.86 (0.63–1.16)

 

1.38 (1.03–1.87)

1.38 (0.96–1.99)

 

 ≥75

466/2614 (17.8)

0.77 (0.62–0.97)

0.97 (0.70–1.35)

 

0.90 (0.69–1.18)

1.27 (0.85–1.89)

 

Sex

   

0.07

  

0.88

 Male

708/12381 (5.7)

0.76 (0.61–0.94)

0.59 (0.45–0.77)

 

1.13 (0.87–1.47)

1.25 (0.89–1.75)

 

 Female

500/3847 (13.0)

0.86 (0.68–1.09)

0.93 (0.68–1.27)

 

1.18 (0.90–1.56)

1.46 (1.01–2.11)

 

Hospital class

   

0.65

  

0.96

 Province-level

251/5256 (4.8)

1.01 (0.66–1.55)

0.87 (0.53–1.43)

 

1.13 (0.70–1.82)

1.19 (0.67–2.10)

 

 Prefecture-level

670/8808 (7.6)

0.76 (0.61–0.94)

0.64 (0.48–0.84)

 

1.13 (0.88–1.45)

1.32 (0.95–1.85)

 

 County-level

287/2164 (13.3)

0.73 (0.54–0.99)

0.75 (0.50–1.12)

 

1.38 (0.93–2.03)

1.69 (1.01–2.83)

 

Time from onset

   

0.055

  

0.01

 <12 h

694/10818 (6.4)

0.69 (0.56–0.85)

0.52 (0.40–0.69)

 

0.99 (0.77–1.27)

0.97 (0.70–1.35)

 

 ≥12 h

503/5284 (9.5)

0.85 (0.66–1.09)

0.87 (0.63–1.20)

 

1.39 (1.03–1.87)

2.06 (1.41–3.01)

 

Primary PCI

   

0.89

  

0.39

 Yes

248/7017 (3.5)

0.77 (0.53–1.13)

0.75 (0.48–1.17)

 

0.85 (0.55–1.30)

0.95 (0.57–1.59)

 

 No

952/9069 (10.5)

0.78 (0.65–0.92)

0.69 (0.54–0.87)

 

1.24 (1.00–1.53)

1.41 (1.06–1.87)

 

Killip class

   

0.07

  

0.10

 I–II

866/14976 (5.8)

0.69 (0.58–0.83)

0.56 (0.44–0.72)

 

1.09 (0.88–1.34)

1.37 (1.02–1.83)

 

 III–IV

332/1181(28.1)

1.07 (0.77–1.50)

0.88 (0.59–1.32)

 

1.47 (0.95–2.28)

1.51 (0.91–2.52)

 

LVEF<40%

   

0.29

  

0.49

 No

362/11683 (3.1)

0.83 (0.61–1.14)

0.62 (0.41–0.92)

 

1.06 (0.76–1.49)

1.01 (0.64–1.60)

 

 Yes

126/929 (13.6)

1.08 (0.62–1.87)

1.11 (0.58–2.10)

 

1.32 (0.70–2.46)

1.23 (0.56–2.68)

 

GRACE score

   

0.88

  

0.89

 ≤140

124/6933 (1.8)

0.83 (0.46–1.49)

0.81 (0.41–1.58)

 

0.95 (0.50–1.79)

1.13 (0.54–2.38)

 

 >140

949/8500 (11.2)

0.94 (0.78–1.14)

0.97 (0.77–1.23)

 

1.15 (0.94–1.40)

1.30 (0.99–1.69)

 
  1. Models were adjusted for age, sex, education, hospital levels, BMI, family history of CAD, prior history of stroke, prior history of COPD, pre-admission aspirin, onset-to-arrival time, pre-admission cardiac arrest, heart rate, systolic blood pressure, plasma creatinine, Killip class, anterior myocardial infarction, reperfusion strategies, and evidence-based medications (aspirin, P2Y12-receptor inhibitor, statin, ACEI/ARB, and β-blocker)
  2. SMuRF Standard modifiable cardiovascular risk factor, PCI Percutaneous coronary intervention, CAD Coronary artery disease, COPD Chronic obstructive pulmonary disease, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker